Astrazeneca PLC ORD SHS $0.25
Astrazeneca PLC ORD SHS $0.25/ GB0009895292 /
AZN
|
2024-11-04 9:00:00 PM
|
Chg.
+20.0000
|
Volume |
Bid2024-11-04 |
Ask2024-11-04 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
11,042.0000GBX
|
+0.18%
|
1.3 mill.
Turnover(GBP): 143.72 mill. |
10,900.0000Bid Size: 30 |
11,900.0000Ask Size: 200 |
171.65 bill.GBP |
- |
- |
Business description
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Management board & Supervisory board
| CEO |
| Pascal Soriot |
| Management board |
| Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
| Supervisory board |
| Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg, Anna Manz |
